BackDuality Biotherapeutics Overview

Duality Biotherapeutics EBIT

Track Duality Biotherapeutics's EBIT ($-1.5B) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow

Quarterly EBIT

-$483.45M
↓ 927.17% YoY

As of Jun 30, 2026

Annual EBIT (TTM)

-$1.54B
↓ 48.58% YoY

Trailing 12 months ending Jun 30, 2026

Average EBIT (Comparison Companies)

EBIT History

EBIT Comparison

Annual EBIT Growth Rate (%)

Annual EBIT Growth (Absolute)

Duality Biotherapeutics (9606.HK) FAQ

The latest EBIT for 9606.HK is $-1.5B as of June 2026. That compares with $-1B in the prior-year period — down 48.6% year over year. That is below the Healthcare sector average of $1.1T. Investors often review this figure alongside Duality Biotherapeutics's historical trend and sector peers before judging valuation or financial health.

Over the past year, 9606.HK's EBIT moved from $-1B to $-1.5B — a 48.6% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Duality Biotherapeutics's operating scale or balance-sheet position.

Against Healthcare companies, 9606.HK currently prints $-1.5B for EBIT, while the sector average sits near $1.1T. That is roughly 100.1% below the sector mean. Large gaps often invite a closer look at Duality Biotherapeutics's growth, margins, and balance sheet.

A EBIT figure of $-1.5B for 9606.HK is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $1.1T. Explore the charts below for those layers of context.

After noting 9606.HK's EBIT ($-1.5B), review year-over-year change from $-1B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

Questions & Answers